After an inspection of Hospira’s medical device quality systems in Lake Forest, Ill., the FDA issued a list of 10 objectionable conditions in a Form 483. So far in 2013, the company has sent out 11 device notifications, including recalls and corrections.
Hospira’s Clayton, N.C., facility recently resumed producing propofol, and plans to re-launch the drug shortly.
More Articles on Anesthesia:
ASA Opposes Proposed FDA Changes to Opioid Labels
5 Points to Consider Before Merging an Anesthesia Practice
Anesthesiologist Dr. Shawn Crook Joins Bothwell Regional Health Center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
